In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

Polo‐like kinase 1 (Plk1), a master regulator of mitosis and the DNA damage response, is considered to be an intriguing target in the research field of mitotic intervention. The observation that Plk1 is overexpressed in multiple human malignancies, including non‐small‐cell lung cancer (NSCLC), gave...

Full description

Bibliographic Details
Main Authors: Jolien Van denBossche, Christophe Deben, Ines De Pauw, Hilde Lambrechts, Christophe Hermans, Vanessa Deschoolmeester, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan Baptist Vermorken, Marc Peeters, Filip Lardon, An Wouters
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Molecular Oncology
Subjects:
hypoxia
non‐small‐cell lung cancer
p53
Polo‐like kinase 1
senescence
volasertib
Online Access:https://doi.org/10.1002/1878-0261.12477

Internet

https://doi.org/10.1002/1878-0261.12477

Similar Items